| Description | KRAS G12C inhibitor 18 is a potent, orally active compound that inhibits KRAS G12C and exhibits anti-tumor activities. |
| In vitro | KRAS G12C inhibitor 18 (compound 34) inhibits the growth of many KRas G12C mutant tumor cell lines (such as H358, SW1436, MiaPaca-2 cells, etc.)[1]. |
| In vivo | KRAS G12C inhibitor 18 exhibits a dose dependent inhibiton of pERK and active KRas after a single dose treatment from 12.5 to 100 mg/kg at 8 hours[1]. KRAS G12C inhibitor 18 (30 mg/kg; p.o.; twice daily) exhibits anti-tumor growth activity in lung cancer H358 xenograft mouse model[1]. |
| molecular weight | 510.97 |
| Molecular formula | C25H20ClFN4O3S |
| CAS | 2649788-45-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Serge Louis Boulet, et al. Kras g12c inhibitors. WO2021118877A1. |